TNFRSF17 and systemic lupus erythematosus: Additionally, sCD40L trimers, which are elevated in SLE, reduce the levels of viable CD180-negative (and CD180-positive) SLE B cells, and this effect is reversed by treatment of B cells with the BCMA ligand APRIL (a proliferation-inducing ligand) (Koarada et al. 2010).